Cargando…

Nucleic acids in inclusion bodies obtained from E. coli cells expressing human interferon-gamma

BACKGROUND: Inclusion bodies (IBs) are protein aggregates in recombinant bacterial cells containing mainly the target recombinant protein. Although it has been shown that IBs contain functional proteins along with protein aggregates, their direct application as pharmaceuticals is hindered by their h...

Descripción completa

Detalles Bibliográficos
Autores principales: Krachmarova, Elena, Ivanov, Ivan, Nacheva, Genoveva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353671/
https://www.ncbi.nlm.nih.gov/pubmed/32652996
http://dx.doi.org/10.1186/s12934-020-01400-6
_version_ 1783557930995417088
author Krachmarova, Elena
Ivanov, Ivan
Nacheva, Genoveva
author_facet Krachmarova, Elena
Ivanov, Ivan
Nacheva, Genoveva
author_sort Krachmarova, Elena
collection PubMed
description BACKGROUND: Inclusion bodies (IBs) are protein aggregates in recombinant bacterial cells containing mainly the target recombinant protein. Although it has been shown that IBs contain functional proteins along with protein aggregates, their direct application as pharmaceuticals is hindered by their heterogeneity and hazardous contaminants with bacterial origin. Therefore, together with the production of soluble species, IBs remain the main source for manufacture of recombinant proteins with medical application. The quality and composition of the IBs affect the refolding yield and further purification of the recombinant protein. The knowledge whether nucleic acids are genuine components or concomitant impurities of the IBs is a prerequisite for the understanding of the IBs formation and for development of optimized protocols for recombinant protein refolding and purification. IBs isolated from Escherichia coli overexpressing human interferon-gamma (hIFNγ), a protein with therapeutic application, were used as a model. RESULTS: IBs were isolated from E. coli LE392 cells transformed with a hIFNγ expressing plasmid under standard conditions and further purified by centrifugation on a sucrose cushion, followed by several steps of sonication and washings with non-denaturing concentrations of urea. The efficiency of the purification was estimated by SDS-PAGE gel electrophoresis and parallel microbiological testing for the presence of residual intact bacteria. Phenol/chloroform extraction showed that the highly purified IBs contain both DNA and RNA. The latter were studied by UV spectroscopy and agarose gel electrophoresis combined with enzymatic treatment and hybridization. DNA was observed as a diffuse fraction mainly in the range of 250 to 1000 bp. RNA isolated by TRIzol(®) also demonstrated a substantial molecular heterogeneity. Hybridization with (32)P-labelled oligonucleotides showed that the IBs contain rRNA and are enriched of hIFNγ mRNA. CONCLUSIONS: The results presented in this study indicate that the nucleic acids might be intrinsic components rather than co-precipitated impurities in the IBs. We assume that the nucleic acids are active participants in the aggregation of recombinant proteins and formation of the IBs that originate from the transcription and translation machinery of the microbial cell factory. Further studies are needed to ascertain this notion.
format Online
Article
Text
id pubmed-7353671
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73536712020-07-14 Nucleic acids in inclusion bodies obtained from E. coli cells expressing human interferon-gamma Krachmarova, Elena Ivanov, Ivan Nacheva, Genoveva Microb Cell Fact Research BACKGROUND: Inclusion bodies (IBs) are protein aggregates in recombinant bacterial cells containing mainly the target recombinant protein. Although it has been shown that IBs contain functional proteins along with protein aggregates, their direct application as pharmaceuticals is hindered by their heterogeneity and hazardous contaminants with bacterial origin. Therefore, together with the production of soluble species, IBs remain the main source for manufacture of recombinant proteins with medical application. The quality and composition of the IBs affect the refolding yield and further purification of the recombinant protein. The knowledge whether nucleic acids are genuine components or concomitant impurities of the IBs is a prerequisite for the understanding of the IBs formation and for development of optimized protocols for recombinant protein refolding and purification. IBs isolated from Escherichia coli overexpressing human interferon-gamma (hIFNγ), a protein with therapeutic application, were used as a model. RESULTS: IBs were isolated from E. coli LE392 cells transformed with a hIFNγ expressing plasmid under standard conditions and further purified by centrifugation on a sucrose cushion, followed by several steps of sonication and washings with non-denaturing concentrations of urea. The efficiency of the purification was estimated by SDS-PAGE gel electrophoresis and parallel microbiological testing for the presence of residual intact bacteria. Phenol/chloroform extraction showed that the highly purified IBs contain both DNA and RNA. The latter were studied by UV spectroscopy and agarose gel electrophoresis combined with enzymatic treatment and hybridization. DNA was observed as a diffuse fraction mainly in the range of 250 to 1000 bp. RNA isolated by TRIzol(®) also demonstrated a substantial molecular heterogeneity. Hybridization with (32)P-labelled oligonucleotides showed that the IBs contain rRNA and are enriched of hIFNγ mRNA. CONCLUSIONS: The results presented in this study indicate that the nucleic acids might be intrinsic components rather than co-precipitated impurities in the IBs. We assume that the nucleic acids are active participants in the aggregation of recombinant proteins and formation of the IBs that originate from the transcription and translation machinery of the microbial cell factory. Further studies are needed to ascertain this notion. BioMed Central 2020-07-11 /pmc/articles/PMC7353671/ /pubmed/32652996 http://dx.doi.org/10.1186/s12934-020-01400-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Krachmarova, Elena
Ivanov, Ivan
Nacheva, Genoveva
Nucleic acids in inclusion bodies obtained from E. coli cells expressing human interferon-gamma
title Nucleic acids in inclusion bodies obtained from E. coli cells expressing human interferon-gamma
title_full Nucleic acids in inclusion bodies obtained from E. coli cells expressing human interferon-gamma
title_fullStr Nucleic acids in inclusion bodies obtained from E. coli cells expressing human interferon-gamma
title_full_unstemmed Nucleic acids in inclusion bodies obtained from E. coli cells expressing human interferon-gamma
title_short Nucleic acids in inclusion bodies obtained from E. coli cells expressing human interferon-gamma
title_sort nucleic acids in inclusion bodies obtained from e. coli cells expressing human interferon-gamma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353671/
https://www.ncbi.nlm.nih.gov/pubmed/32652996
http://dx.doi.org/10.1186/s12934-020-01400-6
work_keys_str_mv AT krachmarovaelena nucleicacidsininclusionbodiesobtainedfromecolicellsexpressinghumaninterferongamma
AT ivanovivan nucleicacidsininclusionbodiesobtainedfromecolicellsexpressinghumaninterferongamma
AT nachevagenoveva nucleicacidsininclusionbodiesobtainedfromecolicellsexpressinghumaninterferongamma